Rezvilutamide
As of the edition of 20 October 2026, Rezvilutamide is a small molecule: in active development; acts on AR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 30, 3 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AR | Androgen receptor | P10275 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 2 | 0 |
| Phase 1 | 7 | 3 | 0 | 0 |
| Phase 2 | 16 | 0 | 10 | 2 |
| Phase 3 | 4 | 0 | 2 | 1 |
| All trials | 30 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2016 to now |
| Atridia | Lead sponsor of trials | 2016 to now |